Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Vibecotamab in CD123-Expressing Hematologic Malignancies
NCT02730312Phase 1Completed
- Sponsor
- Xencor
- Start
- Aug 2016
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vibecotamab in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and 1 more, sponsored by Xencor. Primary endpoints: Number of participants with treatment-related adverse events and Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD). Started Aug 2016; status: completed.
02
Drugs
vibecotamab
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02730312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730312.